Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Current Cancer Drug Targets|October 11, 2024
The Clinicopathological and Prognostic Significance of the Expression of PD-L1 and MET Genes in Breast Cancer: Potential Therapeutic TargetsMuhsen Al-Diabat, Nehad M Ayoub, Laith Al-Eitan, et al.
International Journal of Breast Cancer|June 26, 2024
BRAF Expression and Copy Number Alterations Predict Unfavorable Tumor Features and Adverse Outcomes in Patients With Breast CancerYazan R Alhamdan, Nehad M Ayoub, Sara K Jaradat, et al.
Molecular Endocrinology (Baltimore, Md.)|February 19, 2011
Hormone depletion-insensitivity of prostate cancer cells is supported by the AR without binding to classical response elementsMesfin Gonit, Juan Zhang, Marcela d'Alincourt Salazar, et al.
The Breast Journal|January 1, 2025
The Impact of the Coexpression of MET and ESR Genes on Prognosticators and Clinical Outcomes of Breast Cancer: An Analysis for the METABRIC DatasetNehad M Ayoub, Ghaith M Al-Taani, Amer E Alkhalifa, et al.
Cell Metabolism|April 9, 2013
Molecular and genetic crosstalks between mTOR and ERRα are key determinants of rapamycin-induced nonalcoholic fatty liverCédric Chaveroux, Lillian J Eichner, Catherine R Dufour, et al.
Cancer Control : Journal of the Moffitt Cancer Center|January 24, 2022
Differential Histone Posttranslational Modifications Induced by DNA Hypomethylating AgentsSridhar A Malkaram, Aymen Shatnawi, Jun Fan, et al.
Scientific Reports|September 24, 2020
Author Correction: Activation of SIRT6 by DNA hypomethylating agents and clinical consequences on combination therapy in leukemiaHetty E Carraway, Sridhar A Malkaram, Yana Cen, et al.
Scientific Reports|June 27, 2020
Activation of SIRT6 by DNA hypomethylating agents and clinical consequences on combination therapy in leukemiaHetty E Carraway, Sridhar A Malkaram, Yana Cen, et al.
Pageof 2